General Information of Drug (ID: DMRO6XT)

Drug Name
BGB-290 Drug Info
Synonyms Pamiparib
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Recurrent glioblastoma 2A00.00 Phase 1 [2]
Cross-matching ID
PubChem CID
135565554
CAS Number
CAS 1446261-44-4
TTD Drug ID
DMRO6XT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Olaparib DM8QB1D Ovarian cancer 2C73 Approved [4]
Rucaparib DM9PVX8 Ovarian cancer 2C73 Approved [5]
Talazoparib DM1KS78 Breast cancer 2C60-2C65 Approved [6]
MK-4827 DMLYGH4 Ovarian cancer 2C73 Phase 3 [7]
BSI-201 DMM0VO3 Solid tumour/cancer 2A00-2F9Z Phase 3 [8]
Rubraca rucaparib DM25TMP Ovarian cancer 2C73 Phase 3 [2]
ABT-888 DM4HYMS Breast cancer 2C60-2C65 Phase 3 [7]
INO-1001 DM5L8QT Brain cancer 2A00 Phase 3 [9]
BGP-15 DMYDM68 Type-2 diabetes 5A11 Phase 2 [10]
2X-121 DMX9MSL Breast cancer 2C60-2C65 Phase 2 [2]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Tankyrase (TNKS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
2X-121 DMX9MSL Breast cancer 2C60-2C65 Phase 2 [2]
STP1002 DMXCJP8 Solid tumour/cancer 2A00-2F9Z Phase 1 [11]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Poly [ADP-ribose] polymerase (PARP) TTEBCY8 NOUNIPROTAC Inhibitor [2]
Tankyrase (TNKS) TTKSAQZ NOUNIPROTAC Modulator [3]

References

1 ClinicalTrials.gov (NCT03933761) Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy (PRECISE). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 National Cancer Institute Drug Dictionary (drug id 769217).
4 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
5 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
6 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
7 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
8 Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012 Mar 15;18(6):1655-62.
9 Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock. 2010 May;33(5):507-12.
10 BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37.
11 Design and development of a tankyrase inhibitor STP06-1002 as an anticancer therapeutic agent. Cancer Res 2017;77(13 Suppl):Abstract nr 5171.